Samanta Lalic1, Janet K Sluggett2, Jenni Ilomäki3, Barbara C Wimmer4, Edwin C K Tan5, Leonie Robson6, Tina Emery6, J Simon Bell7. 1. Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia; Pharmacy Department, Austin Health, Melbourne, Australia. Electronic address: Samanta.Lalic@monash.edu. 2. Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia; NHMRC Cognitive Decline Partnership Center, Hornsby Ku-ring-gai Hospital, Hornsby, New South Wales, Australia. 3. Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia; School of Public Health and Preventative Medicine, Monash University, Melbourne, Australia. 4. Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia; Division of Pharmacy, School of Medicine, University of Tasmania, Hobart, Tasmania, Australia. 5. Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia; Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, Stockholm, Sweden. 6. Resthaven Incorporated, Adelaide, Australia. 7. Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia; NHMRC Cognitive Decline Partnership Center, Hornsby Ku-ring-gai Hospital, Hornsby, New South Wales, Australia; Sansom Institute, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia.
Abstract
OBJECTIVES: To investigate the association between polypharmacy and medication regimen complexity with time to first hospitalization, number of hospitalizations, and number of hospital days over a 12-month period. DESIGN: A 12-month prospective cohort study. PARTICIPANTS AND SETTING: A total of 383 residents of 6 Australian long-term care facilities (LTCFs). MEASUREMENTS: The primary exposures were polypharmacy (≥9 regular medications) and the 65-item Medication Regimen Complexity Index (MRCI). Cox proportional hazards regression was used to compute hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between polypharmacy and MRCI with time to first hospitalization. Poisson regression was used to compute incident rate ratios (IRR) and 95% CIs for the association between polypharmacy and MRCI with number of hospitalizations and number of hospital days. Models were adjusted for age, sex, length of stay in LTCF, comorbidities, activities of daily living, and dementia severity. RESULTS: There were 0.56 (95% CI 0.49-0.65) hospitalizations per person-year and 4.52 (95% CI 4.31-4.76) hospital days per person-year. In adjusted analyses, polypharmacy was associated with time to first hospitalization (HR 1.84; 95% CI 1.21-2.79), number of hospitalizations (IRR 1.51; 95% CI 1.09-2.10), and hospital days per person-year (IRR 1.39; 95% CI 1.24-1.56). Similarly, in adjusted analyses a 10-unit increase in MRCI was associated with time to first hospitalization (HR 1.17; 95% CI 1.06-1.29), number of hospitalizations (IRR 1.15; 95% CI 1.06-1.24), and hospital days per person-year (IRR 1.19; 95% CI 1.16-1.23). CONCLUSIONS: Polypharmacy and medication regimen complexity are associated with hospitalizations from LTCFs. This highlights the importance of regular medication review for residents of LTCFs and the need for further research into the risk-to-benefit ratio of prescribing in this setting.
OBJECTIVES: To investigate the association between polypharmacy and medication regimen complexity with time to first hospitalization, number of hospitalizations, and number of hospital days over a 12-month period. DESIGN: A 12-month prospective cohort study. PARTICIPANTS AND SETTING: A total of 383 residents of 6 Australian long-term care facilities (LTCFs). MEASUREMENTS: The primary exposures were polypharmacy (≥9 regular medications) and the 65-item Medication Regimen Complexity Index (MRCI). Cox proportional hazards regression was used to compute hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between polypharmacy and MRCI with time to first hospitalization. Poisson regression was used to compute incident rate ratios (IRR) and 95% CIs for the association between polypharmacy and MRCI with number of hospitalizations and number of hospital days. Models were adjusted for age, sex, length of stay in LTCF, comorbidities, activities of daily living, and dementia severity. RESULTS: There were 0.56 (95% CI 0.49-0.65) hospitalizations per person-year and 4.52 (95% CI 4.31-4.76) hospital days per person-year. In adjusted analyses, polypharmacy was associated with time to first hospitalization (HR 1.84; 95% CI 1.21-2.79), number of hospitalizations (IRR 1.51; 95% CI 1.09-2.10), and hospital days per person-year (IRR 1.39; 95% CI 1.24-1.56). Similarly, in adjusted analyses a 10-unit increase in MRCI was associated with time to first hospitalization (HR 1.17; 95% CI 1.06-1.29), number of hospitalizations (IRR 1.15; 95% CI 1.06-1.24), and hospital days per person-year (IRR 1.19; 95% CI 1.16-1.23). CONCLUSIONS: Polypharmacy and medication regimen complexity are associated with hospitalizations from LTCFs. This highlights the importance of regular medication review for residents of LTCFs and the need for further research into the risk-to-benefit ratio of prescribing in this setting.
Authors: Taliesin E Ryan-Atwood; Mieke Hutchinson-Kern; Jenni Ilomäki; Michael J Dooley; Susan G Poole; Carl M Kirkpatrick; Elizabeth Manias; Biswadev Mitra; J Simon Bell Journal: Drugs Aging Date: 2017-08 Impact factor: 3.923
Authors: Kate N Wang; J Simon Bell; Edwin C K Tan; Julia F M Gilmartin-Thomas; Michael J Dooley; Jenni Ilomäki Journal: Drugs Aging Date: 2019-11 Impact factor: 3.923
Authors: Julia M T Colombijn; Anna A Bonenkamp; Anita van Eck van der Sluijs; Joost A Bijlsma; Arnold H Boonstra; Akin Özyilmaz; Alferso C Abrahams; Brigit C van Jaarsveld Journal: Am J Nephrol Date: 2021-09-10 Impact factor: 3.754
Authors: María Luisa Ibarra Mira; Jose Manuel Caro-Teller; Pedro Pablo Rodríguez Quesada; Carmen Garcia-Muñoz; Almudena Añino Alba; Jose Miguel Ferrari Piquero Journal: J Pharm Technol Date: 2021-09-22
Authors: Janet K Sluggett; Esa Y H Chen; Jenni Ilomäki; Megan Corlis; Sarah N Hilmer; Jan Van Emden; Choon Ean Ooi; Kim-Huong Nguyen; Tracy Comans; Michelle Hogan; Tessa Caporale; Susan Edwards; Lyntara Quirke; Allan Patching; J Simon Bell Journal: Trials Date: 2018-01-12 Impact factor: 2.279
Authors: Michael R Cobretti; Robert L Page; Sunny A Linnebur; Kimberly M Deininger; Amrut V Ambardekar; JoAnn Lindenfeld; Christina L Aquilante Journal: Clin Interv Aging Date: 2017-04-12 Impact factor: 4.458
Authors: Esa Yh Chen; Janet K Sluggett; Jenni Ilomäki; Sarah N Hilmer; Megan Corlis; Leonie J Picton; Laura Dean; Christopher P Alderman; Nicholas Farinola; Joy Gailer; Jane Grigson; Andrew R Kellie; Peter Jc Putsey; Solomon Yu; J Simon Bell Journal: Clin Interv Aging Date: 2018-05-18 Impact factor: 4.458
Authors: Janet K Sluggett; Georgina A Hughes; Choon Ean Ooi; Esa Y H Chen; Megan Corlis; Michelle E Hogan; Tessa Caporale; Jan Van Emden; J Simon Bell Journal: Int J Environ Res Public Health Date: 2021-05-27 Impact factor: 3.390